Results 151 to 160 of about 53,742 (236)

Pharmacogenomics and Big Data in medical oncology: developments and challenges

Therapeutic Advances in Medical Oncology
Medical oncology, through conventional chemotherapy as well as targeted drugs, remains an important component of cancer patient management, particularly for systemic disease.
Loredana G. Marcu, David C. Marcu
doaj   +1 more source

Assessment of knowledge, perceptions, and readiness of healthcare professionals towards clinical pharmacogenomics implementation in Qatar: a mixed-method study

Journal of Pharmaceutical Policy and Practice
Introduction Pharmacogenomics implementation in clinical practice is anticipated to improve our understanding of individual variations in drug response and optimise the safety and efficacy of drug therapy.
Shaikha Jabor Alnaimi, Fatima Ajaj, Ahmed Awaisu, Turfa Alhathal, Shaban Mohammed, Moza Alhail   +5 more
doaj   +1 more source

Pharmacogenomics and schizophrenia: clinical implications [PDF]

, 2001
Anil K. Malhotra
openalex   +1 more source

Pathway‐level mutational signatures predict breast cancer outcomes and reveal therapeutic targets

British Journal of Pharmacology, Volume 182, Issue 23, Page 5734-5747, December 2025.
Abstract Background and Purpose In order to significantly improve the therapeutic treatment of breast cancer, the exploration of underlying genetic and molecular differences is absolutely necessary. Here, our goal was to integrate mutational status of entire pathways to reveal molecular pathway interactions determining survival. Experimental Approach A
Máté Posta, Balázs Győrffy
wiley   +1 more source

Pharmacogenomics: The promise of personalized medicine

, 2000
Laviero Mancinelli, Maureen Cronin, Wolfgang Sadée   +2 more
openalex   +2 more sources

Recurrent fexuprazan‐induced liver injury following unintentional re‐exposure

British Journal of Clinical Pharmacology, Volume 91, Issue 11, Page 3266-3271, November 2025.
Fexuprazan, a potassium‐competitive acid blocker, is increasingly used for the treatment of gastroesophageal reflux disease in South Korea. While generally well tolerated, data regarding its hepatotoxic potential are scarce. We report a case of idiosyncratic drug‐induced liver injury in a 61‐year‐old woman following 2 months of fexuprazan therapy.
Sook Jin Seong, O Seong Kweon, Young‐Ran Yoon, Yu Kyung Kim, Yoo Na Kang, Se Young Jang   +5 more
wiley   +1 more source

Assessing the cost-effectiveness of pharmacogenomics

, 2000
David L. Veenstra, Mitchell K. Higashi, Kathryn A. Phillips   +2 more
openalex   +2 more sources

Effectiveness and Safety of Perampanel in Refractory Focal Epilepsy: Real‐World Evidence From a Chinese Cohort

Brain and Behavior, Volume 15, Issue 11, November 2025.
This retrospective real‐world study of 190 Chinese patients with refractory focal epilepsy demonstrated that adjunctive PER achieved sustained responder rates (∼66%) and seizure freedom (∼27%) over 12 months, with an acceptable safety profile. Male gender, higher doses, and late add‐on predicted better outcomes, while adults experienced fewer adverse ...
Tong Yi, Luwen Huang, Wei Peng, Ting Zhang, Dong Zhou, Xiaohui Lai, Jinmei Li   +6 more
wiley   +1 more source

Pharmacogenomics: Revolution in a Bottle? [PDF]

, 2002
Faith Lagay
openalex   +1 more source

Association of Germline Single Nucleotide Polymorphisms in Steroid Hormone Metabolism Pathway With Androgen Deprivation Therapy Prognosis of Prostate Cancer in Chinese Population

Cancer Medicine, Volume 14, Issue 21, November 2025.
ABSTRACT Background Single nucleotide polymorphisms (SNPs) located in the genes participating in the steroid hormone metabolism pathway may influence the outcomes of androgen deprivation therapy (ADT) in prostate cancer (PCa) patients, but findings on the Chinese population remain limited.
Ruofan Shi, Xiaohao Ruan, Qijun Du, Tsun Tsun Stacia Chun, Da Huang, Kuen Chan, Yuguang Philip Wu, Tsz Yeung Kam, Danfeng Xu, Rong Na   +9 more
wiley   +1 more source